Kura Oncology, Inc. (NASDAQ:KURA) has earned a consensus recommendation of “Buy” from the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $22.60.
A number of equities analysts have recently issued reports on KURA shares. Zacks Investment Research lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. Citigroup set a $28.00 target price on shares of Kura Oncology and gave the stock a “buy” rating in a research report on Friday, February 16th. Cann reiterated a “buy” rating and set a $30.00 target price on shares of Kura Oncology in a research report on Friday, February 16th. BidaskClub upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research report on Friday, December 22nd. Finally, Wedbush started coverage on shares of Kura Oncology in a research report on Wednesday, December 20th. They set an “outperform” rating and a $19.00 target price on the stock.
Hedge funds have recently made changes to their positions in the company. New York State Common Retirement Fund acquired a new position in shares of Kura Oncology during the second quarter worth approximately $142,000. MetLife Investment Advisors LLC acquired a new position in Kura Oncology in the fourth quarter valued at approximately $155,000. American International Group Inc. lifted its holdings in Kura Oncology by 42.0% in the fourth quarter. American International Group Inc. now owns 13,574 shares of the company’s stock valued at $208,000 after buying an additional 4,012 shares during the period. Schwab Charles Investment Management Inc. acquired a new position in Kura Oncology in the second quarter valued at approximately $226,000. Finally, California State Teachers Retirement System acquired a new position in Kura Oncology in the second quarter valued at approximately $235,000. Institutional investors own 62.83% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Kura Oncology, Inc. (KURA) Receives Consensus Rating of “Buy” from Analysts” was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3229208/kura-oncology-inc-kura-receives-consensus-rating-of-buy-from-analysts.html.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.